News

CRISPRMED24 Poster Prize Winners

We congratulate the 8 poster winners at CRISPRMED24 who won a certificate and free registration to CRISPRMED25.

By: Karen O'Hanlon Cohrt - Apr. 29, 2024
News
  • Rodrigo Coronel Tellez, Postdoc at Danish Technical University: Efficient sortase-mediated assembly of CRISPR-Cas9
  • Colette Rogers, Postdoc at University of Minnesota: In Vivo Correction of a Genetically Humanized Fanconi Anemia Mouse Model Using Digital Editing Technologies
  • Helena Escobar, Postdoc at Max-Delbrück Center - Charite, Berlin: Gene-edited primary muscle stem cells rescue dysferlin-deficient muscular dystrophy
  • Federica Zinghirino, Postdoc at University College London: Development of a CRISPR-based epigenome editing platform to enhance the long-term engraftment of ex-vivo genetically modified HSPCs
  • Issa Ismail, PhD fellow at Aalborg University, Denmark: Genome-wide CRISPR-Cas9 knockout screen identifies DNA damage response pathways and BTK as essential for cisplatin response in diffuse large B-cell lymphoma
  • Laura Castilla-Vallmanya, Postdoc at Lund Stem Cell Centre, Sweden: Studying the role of TRIM28 and transposable elements dysregulation in neurodevelopmental disorders using CRISPRed in vitro models
  • Roberta Vacca, PhD student at San Raffaele Telethon Institute for Gene Therapy, Italy: p38 MAPK fuels proliferation stress and DNA damage impairing the functionality of genetically engineered hematopoietic stem and progenitor cells
  • Pietro De Angeli, Scientist, University Hospital Tübingen, Germany: EDSpliCE: A Novel Gene Editing Platform Holding Therapeutic Potential for Splicing Modulation in Inherited Retinal Disorders

Tags

HashtagArticleHashtagCRISPRMED24HashtagCRISPRMED24 Landing-page

News: CRISPRMED24 Poster Prize Winners
CLINICAL TRIALS
Chronic Hepatitis B, HBV, (NCT06680232)
Sponsors:
Precision BioSciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Duchenne Muscular Dystrophy, DMD, (NCT06594094)
Sponsors:
HuidaGene Therapeutics Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine